Active not recruitingPHASE2INTERVENTIONAL

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

This study, called TAPISTRY, is for individuals in the UK with advanced solid cancers that are difficult to treat or have spread. It's a Phase II trial, meaning it's testing new treatments and combinations. The core idea is "precision medicine": instead of a one-size-fits-all approach, doctors will look at the unique genetic makeup of your tumour using a special test. Based on these genetic findings, you'll receive a treatment tailored specifically for your cancer. This could be a new drug or a combination of drugs. The goal is to see if these targeted treatments are safe and effective, aiming to offer a more personalised way to fight cancer than traditional methods.

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

Hoffmann-La Roche

Enrolment target

920

Start

18 Jan 2021

Estimated completion

25 Sep 2032

Solid Tumors

What is this study about?

The TAPISTRY study is designed for individuals in the UK who have advanced solid cancers that have either spread to other parts of the body (metastatic) or cannot be removed through surgery. It's a type of research called a 'Phase II' clinical trial, which means it’s testing how well new treatments work and if they are safe, often in a larger group of people than earlier studies.

The main idea behind this study is 'precision medicine' – tailoring treatments specifically to you. We know that every cancer is unique, often due to specific genetic blueprints within the cancer cells. In this study, doctors will take a sample of your cancer and perform a special test called 'next-generation sequencing'. This test looks closely at the genes in your tumour to identify any particular changes or 'alterations'.

Once these genetic changes are identified, you will be matched to a specific treatment or a combination of treatments from a list of options being studied. These treatments are chosen because they are designed to specifically target the genetic changes found in your cancer. This personalised approach aims to be more effective than standard treatments and reduce side effects by focusing only on the cancer cells. Treatment will continue until your cancer gets worse, the side effects become too much, or you or your doctor decide to stop.

Key takeaways

Targets advanced solid cancers that are hard to treat.
Uses a 'precision medicine' approach by matching treatment to your tumour's genes.
Investigates new drugs and combinations for safety and effectiveness.
Offers a personalised treatment path based on your unique cancer profile.
Participation involves genetic testing, treatment, and ongoing monitoring.

Who may be eligible?

To be considered for this study, you generally need to have a solid cancer that has either spread or can't be removed by surgery. Your cancer must also be measurable, which means doctors can track its size and how it responds to treatment. You should be well enough to take part in the study, meaning you are able to do most of your daily activities, and your organs like your kidneys and liver are working properly. Your cancer should have progressed after previous treatments, or you might have a type of cancer for which there isn't a standard, proven treatment yet.

There are also some specific things that would mean you couldn't join. For example, if you are already taking part in another clinical trial that involves a new treatment, or if you've recently had other cancer treatments. Pregnant or breastfeeding individuals cannot participate, nor can those intending to become pregnant during the study. If you have other significant medical conditions that could make taking part unsafe, you might also be excluded. You will also need to meet specific criteria unique to the particular treatment group (cohort) you might be placed in, based on your tumour's genetic changes.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do I have a solid cancer that is advanced or has spread?
Am I generally well enough to participate in a study, able to manage daily tasks?
Are my major organs (like liver, kidneys) working reasonably well?
Have I either progressed on previous treatments, or is my cancer type currently lacking standard treatment options?
Am I not pregnant or breastfeeding, and not intending to become pregnant during the study?

Answer every question to see your result.

What does participation involve?

If you join the TAPISTRY study, the first step will involve having a special genetic test done on your cancer cells to understand their unique makeup. Based on these results, you'll be matched to a specific treatment or combination of treatments from the study. You will receive this study medication. You'll have regular visits to the hospital for checks, which will include physical examinations, blood tests, and scans to see how you're responding to the treatment and to monitor for any side effects.

The frequency of visits and specific tests will depend on the treatment you receive, but you can expect periodic assessments. Treatment will continue as long as it's helping you and any side effects are manageable, or until your doctor decides it's no longer the best option. There will also be follow-up appointments after you stop receiving the study treatment to monitor your health. The total duration of your participation will vary depending on your response to treatment.

Potential risks and benefits

Taking part in this study could offer you access to new, targeted treatments that might be more effective for your specific cancer type than standard options, potentially leading to better outcomes or managing side effects more effectively. However, like all medications, the treatments in this study can have side effects, which could range from mild to serious. Because these are new approaches, not all side effects are fully known. You will be closely monitored for any reactions, and your safety is a top priority. As with any clinical trial, there's no guarantee that the treatment will work for you. Remember, you have the right to withdraw from the study at any time, for any reason, without affecting your standard medical care.

Locations (114)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Western Regional Medical Center at Cancer Treatment Centers of America
Verified postcode
Goodyear, United States
Kaiser Permanente Los Angeles
Verified postcode
Los Angeles, United States
USC Norris Cancer Center
Verified postcode
Los Angeles, United States
Hoag Memorial Hospital
Verified postcode
Newport Beach, United States
UC Davis Comprehensive Cancer Center
Verified postcode
Sacramento, United States
University Cancer & Blood Center, LLC
Verified postcode
Athens, United States
St. Alphonsus
Verified postcode
Boise, United States
Midwestern Regional Med Center
Verified postcode
Zion, United States
Horizon Oncology Research, Inc.
Verified postcode
Lafayette, United States
Maryland Hematology & Oncology. P.A.
Verified postcode
Silver Spring, United States
Henry Ford Health System
Verified postcode
Detroit, United States
Metro-Minnesota Community Oncology Research Consortium
Verified postcode
Saint Louis Park, United States

Common questions

What does 'solid tumours' mean?

Solid tumours are cancers that form a lump or mass, rather than cancers of the blood like leukaemia.

What does 'precision medicine' mean in this study?

It means your treatment will be chosen based on the unique genetic changes found in your specific cancer cells, making it more personalised.

Will I know which drug I'm getting?

Yes, this is an 'open-label' study, meaning you and your doctor will know exactly which treatment you are receiving.

How long will I be on the treatment?

You will receive treatment as long as it's helping you, or until side effects are too much, or you or your doctor decide to stop.

Can I still get my usual cancer care if I join?

Yes, but you cannot be participating in another clinical trial that uses new therapeutic treatments at the same time.